[1]
|
D’Cruz, D.P. (2006) Antiphospholipid (Hughes) Syndrome: An Overview. In: Khamashta, M.A., Ed., Huges Syn-drome, Springer-Verlag, London, 9-21. https://doi.org/10.1007/1-84628-009-5_2
|
[2]
|
Pattison, N.S., Chamley, L.W., McKay, E.J., Liggins, G.C. and Butler, W.S. (1993) Antiphospholipid Antibodies in Pregnancy: Prevalence and Clinical Associations. British Journal of Obstetrics and Gynaecology, 100, 909-913.
https://doi.org/10.1111/j.1471-0528.1993.tb15105.x
|
[3]
|
Birdsall, M., Pattison, N. and Chamley, L. (1992) Antiphospholipid Antibodies in Pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 32, 328-330. https://doi.org/10.1111/j.1479-828X.1992.tb02844.x
|
[4]
|
Lockwood, C.J., Romero, R., Feinberg, R.F., Clyne, L.P., Coster, B. and Hobbins, J.C. (1989) The Prevalence and Biologic Significance of Lupus Anticoagulant and Anticardiolipin Antibodies in a General Obstetric Population. American Journal of Obstetrics & Gynecology, 161, 369-373. https://doi.org/10.1016/0002-9378(89)90522-X
|
[5]
|
Petri, M. (2006) Epidemiology of Antiphospholipid Antibody Syndrome. In: Khamashta, M.A., Ed., Huges Syndrome, Springer-Verlag, London, 22-28. https://doi.org/10.1007/1-84628-009-5_3
|
[6]
|
Rai, R.S., Clifford, K., Cohen, H. and Regan, L. (2005) High Prospective Fetal Loss Rate in Untreated Pregnancies of Women with Recurrent Miscarriage and Antiphospholipid Antibodies. Human Reproduction, 10, 3301-3304.
https://doi.org/10.1093/oxfordjournals.humrep.a135907
|
[7]
|
Yasuda, M., Takakuwa, K., Tokunaga, A. and Tanaka, K. (1995) Prospective Studies of the Association between Anticardiolipin Antibody and Outcome of Pregnancy. Obstetrics & Gynecology, 86, 555-559.
https://doi.org/10.1016/0029-7844(95)00247-O
|
[8]
|
Allen, J.L., Tapia-Santiago, C. and Kutteh, W.H. (1996) Antiphospholipid Antibodies in Patients with Preeclampsia. American Journal of Reproductive Immunology, 36, 81-85. https://doi.org/10.1111/j.1600-0897.1996.tb00143.x
|
[9]
|
Branch, D.W.M., Andres, R.M., Digre, K.B.M., Rote, N.S.P. and Scott, J.R.M. (1989) The Association of Antiphospholipid Antibodies with Severe Preeclampsia. Obstetrics & Gynecology, 73, 541-545.
|
[10]
|
Katano, K., Aoki, K., Sasa, H., Ogasawara, M., Matsuura, E. and Yagami, Y. (1996) Beta 2-Glycoprotein I-Dependent Anticardiolipin Antibodies as a Predictor of Adverse Pregnancy Outcomes in Healthy Pregnant Women. Human Reproduction, 11, 509-512. https://doi.org/10.1093/HUMREP/11.3.509
|
[11]
|
Harris, E., Chan, J.H., Asherson, R.A., Aber, V.R., Gharavi, A.E. and Hughes, G.V. (1986) Thrombosis, Recurrent Fetal Loss, and Thrombocytopenia: Predictive Value of the Anticardiolipin Antibody Test. Archives of Internal Medicine, 146, 2153-2156. https://doi.org/10.1001/archinte.1986.00360230069012
|
[12]
|
Harris, E.N., Boey, M.L., Mackworth-Young, C.G., Gharavi, A.E., Patel, B.M., Loizou, S. and Hughes, G.R.V. (1983) Anticardiolipin Antibodies: Detection by Radioimmunoassay and Association with Thrombosis in Systemic Lupus Erythematosus. The Lancet, 322, 1211-1214. https://doi.org/10.1016/S0140-6736(83)91267-9
|
[13]
|
Reynaud, Q., Lega, J., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P. and Laporte, S. (2014) Risk of Venous and Arterial Thrombosis according to Type of Antiphospholipid Antibodies in Adults without Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 13, 595-608.
https://doi.org/10.1016/j.autrev.2013.11.004
|
[14]
|
Wahl, D., Guillemin, F., de Maistre, E., Perret-Guillaume, C., Lecompte, T. and Thibaut, G. (1998) Meta-Analysis of the Risk of Venous Thrombosis in Individuals with Antiphospholipid Antibodies without Underlying Autoimmune Disease or Previous Thrombosis. Lupus, 7, 15-22. https://doi.org/10.1191/096120398678919688
|
[15]
|
Cabral, A.R., Cabiedes, J. and Alarcón-Segovia, D. (2004) Heterogeneity of Antibodies to Beta2-Glycoprotein 1 from Patients with Systemic Lupus Erythematosus. Lupus, 13, 182-187. https://doi.org/10.1191/0961203303lu531oa
|
[16]
|
Jong, P.G.D., Quenby, S., Bloemenkamp, K.W., Braams-Lisman, B.A., de Bruin, J.P., Coomarasamy, A., David, M., DeSancho, M.T., van der Heijden, O.W., Hoek, A., Hutten, B.A., Jochmans, K., Koks, C.A., Kuchenbecker, W.K., Mol, B.W., Torrance, H.L., Scheepers, H.C., Stephenson, M.D., Verhoeve, H.R., Visser, J., de Vries, J.I., Goddijn, M. and Middeldorp, S. (2015) ALIFE2 Study: Low-Molecular-Weight Heparin for Women with Recurrent Miscarriage and Inherited Thrombophilia—Study Protocol for a Randomized Controlled Trial. Trials, 16, 208.
https://doi.org/10.1186/s13063-015-0719-9
|
[17]
|
Check, J.H. (2012) The Use of Heparin for Preventing Miscarriage. American Journal of Reproductive Immunology, 67, 326-333. https://doi.org/10.1111/j.1600-0897.2012.01119.x
|
[18]
|
Fouda, U.M., Sayed, A.M., Abdou, A.M., Ramadan, D.I., Fouda, I.M. and Zaki, M.M. (2010) Enoxaparin versus Unfractionated Heparin in the Management of Recurrent Abortion Secondary to Antiphospholipid Syndrome. International Journal of Gynecology & Obstetrics, 112, 211-215. https://doi.org/10.1016/j.ijgo.2010.09.010
|
[19]
|
(2015) Correction to Dosage in: Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis: 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 148, 1529.
|
[20]
|
Bouvier, S., Cochery-Nouvellon, E., GéraldineLavigne-Lissalde, G., Mercier, E., Marchetti, T., Balducchi, J.P., Marès, P. and Gris, J.C. (2013) Comparative Incidence of Pregnancy Outcomes in Treated Obstetric Antiphospholipid Syndrome: The NOH-APS Observational Study. Blood, 123, 404-413. https://doi.org/10.1182/blood-2013-08-522623
|
[21]
|
Bramham, K., Hunt, B.J., Germain, S., Calatayud, I., Khamashta, M., Bewley, S. and Nelson-Piercy, C. (2010) Pregnancy Outcome in Different Clinical Phenotypes of Antiphospholipid Syndrome. Lupus, 19, 58-64.
https://doi.org/10.1177/0961203309347794
|
[22]
|
Zhao, Q.T., Guo, Q.M., Wang, P. and Wang, Q. (2012) Salvianic Acid a Inhibits Lipopolysaccharide-Induced Apoptosis through Regulating Glutathione Peroxidase Activity and Malondialdehyde Level in Vascular Endothelial Cells. Chinese Journal of Natural Medicines, 10, 53-57. https://doi.org/10.3724/SP.J.1009.2012.00053
|
[23]
|
季亢挺, 唐疾飞, 陈鹏, 等. 丹参素保护内皮祖细胞炎症损伤的机制研究[J]. 中国预防医学杂志, 2010, 11(8): 809-812.
|
[24]
|
Zhang, J.P., Zhang, Y.Y., Zhang, Y., Gao, Y.G., Ma, J.J., Wang, N., Wang, J.Y., Xie, Y., Zhang, F.H. and Chu, L. (2013) Salvia Miltiorrhiza (Danshen) Injection Ameliorates Iron Overload-Induced Cardiac Damage in Mice. Planta Medica, 79, 744-752. https://doi.org/10.1055/s-0032-1328588
|
[25]
|
边金铎, 邓同乐, 许健, 等. 丹参素对H2O2诱导的内皮细胞氧化损伤的保护作用研究[J]. 上海中医药大学学报, 2012, 25(3): 61-65.
|
[26]
|
曹金仪. 丹参的化学成分及临床用途[J]. 中国医药指南, 2012, 10(29): 53-55.
|
[27]
|
裴艳霞. 川芎的药理作用及临床应用[J]. 中国医药指南, 2011, 9(34): 197-198.
|
[28]
|
Wu, X.F., Zhang, F., Xiong, X., Lu, C., Lian, N., Lu, Y. and Zheng, S. (2015) Tetramethylpyrazine Reduces Inflammation in Liver Fibrosis and Inhibits Inflammatory Cytokine Expression in Hepatic Stellate Cells by Modulating NLRP3 Inflammasome Pathway. IUBMB Life, 67, 312-321. https://doi.org/10.1002/iub.1348
|
[29]
|
杨文辉, 龚国清, 周怡, 等. 川芎嗪体内抗血栓活性及机制探究[J]. 中国临床药理学与治疗学, 2012, 17(3): 241-245.
|
[30]
|
Cai, X.X., Chen, Z., Pan, X.K., Xia, L., Chen, P., Yang, Y., Hu, H., Zhang, J., Li, K., Ge, J., Yu, K. and Zhuang, J. (2014) Inhibition of Angiogenesis, Fibrosis and Thrombosis by Tetramethylpyrazine: Mechanisms Contributing to the SDF-1/CXCR4 Axis. PLoS ONE, 9, e88176. https://doi.org/10.1371/journal.pone.0088176
|
[31]
|
Xu, Q., Xia, P., Li, X., Wang, W., Liu, Z. and Gao, X. (2014) Tetramethylpyrazine Ameliorates High Glucose-Induced Endothelial Dysfunction by Increasing Mitochondrial Biogenesis. PLoS ONE, 9, e88243.
https://doi.org/10.1371/journal.pone.0088243
|